NewAmsterdam Pharma Company N.V.
Stock Forecast, Prediction & Price Target
NewAmsterdam Pharma Company N.V. (NAMS) stock Price Target by analysts
$41
Potential upside: 67.68%
NewAmsterdam Pharma Company N.V. price prediction
What is NewAmsterdam Pharma Company N.V. stock analysts` prediction?
NewAmsterdam Pharma Company N.V. stock forecast: Based on 2 Wall Street analysts` predicted price targets for NewAmsterdam Pharma Company N.V. in the last 3 months, the avarage price target is $41, with a high forecast of $NaN. The average price target represents a 67.68% change from the last price of $24.45.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
NewAmsterdam Pharma Company N.V. stock Price Target by analysts
Full breakdown of analysts given NewAmsterdam Pharma Company N.V. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Roanna Ruiz Leerink Partners | 0% 0/1 | 10 months ago | $45 84.04% upside | $20.01 | StreetInsider | Previous targets (0) |
Yasmeen Rahimi Piper Sandler | 0% 0/1 | 12 months ago | $37 51.32% upside | $15.95 | StreetInsider | Previous targets (0) |
Serge Belanger Needham | 0% 0/1 | about 1 year ago | $36 47.23% upside | $16.77 | TheFly | Previous targets (0) |
NewAmsterdam Pharma Company N.V. Financial Estimates
NewAmsterdam Pharma Company N.V. Revenue Estimates
NewAmsterdam Pharma Company N.V. EBITDA Estimates
NewAmsterdam Pharma Company N.V. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $97.5M 0% | $12.76M -86.91% | Avg: $6.87M Low: $4.29M High: $11.03M avg. -46.13% | Avg: $19.44M Low: $12.13M High: $31.21M avg. 182.79% | Avg: $131.12M Low: $81.83M High: $210.51M avg. 574.46% | Avg: $320.22M Low: $199.83M High: $514.09M avg. 144.20% |
Net Income
% change YoY
| $-28.81M N/A | $-148.88M -416.68% | $-176.93M -18.84% | Avg: $-129.03M Low: $-153.23M High: $-94.35M avg. 27.07% | Avg: $-123.69M Low: $-221.04M High: $-63.24M avg. 4.14% | Avg: $-86.98M Low: $-155.44M High: $-44.47M avg. 29.67% | Avg: $5.00M Low: $2.55M High: $8.94M avg. 105.75% |
EBITDA
% change YoY
| $-29.81M N/A | $-6.87M 76.93% | $-176.86M -2471.77% | Avg: $1.59M Low: $996.94K High: $2.56M avg. 100.90% | Avg: $4.51M Low: $2.81M High: $7.25M avg. 182.79% | Avg: $30.46M Low: $19.01M High: $48.91M avg. 574.46% | Avg: $74.40M Low: $46.43M High: $119.45M avg. 144.20% |
EPS
% change YoY
| -$1.62 N/A | -$7.85 -384.56% | -$2.15 72.61% | Avg: -$1.57 Low: -$1.87 High: -$1.15 avg. 26.95% | Avg: -$1.51 Low: -$2.69 High: -$0.77 avg. 4.14% | Avg: -$1.06 Low: -$1.89 High: -$0.54 avg. 29.67% | Avg: $0.06 Low: $0.03 High: $0.11 avg. 105.75% |
Operating Expenses
% change YoY
| $29.83M N/A | $104.46M 250.12% | $197.05M 88.64% | Avg: $7.45M Low: $4.65M High: $11.96M avg. -96.21% | Avg: $21.08M Low: $13.15M High: $33.84M avg. 182.79% | Avg: $142.19M Low: $88.73M High: $228.28M avg. 574.46% | Avg: $347.24M Low: $216.69M High: $557.47M avg. 144.20% |
FAQ
What is NewAmsterdam Pharma Company N.V. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 41.66% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -153.23M, average is -129.03M and high is -94.35M.
What is NewAmsterdam Pharma Company N.V. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 213.83% in 2025-2028.
We have gathered data from 4 analysts. Their low revenue estimate is $4.29M, average is $6.87M and high is $11.03M.
What is NewAmsterdam Pharma Company N.V. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 41.63% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$1.87, average is -$1.57 and high is $-1.14.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering NewAmsterdam Pharma Company N.V. stock. The most successful analyst is Roanna Ruiz.